[A23-02] Olaparib (breast cancer, adjuvant) – Addendum to Commission A22-89
Last updated 16.02.2023
Project no.:
A23-02
Commission:
Commission awarded on 10.01.2023 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adult patients with germline BRCA-mutant, HER2-negative, high risk early breast cancer; after neoadjuvant or adjuvant chemotherapy; adjuvant treatment
Unchanged after addendum: indication of minor added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A22-89 | Olaparib (breast cancer, adjuvant) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2023-02-16 A G-BA decision was published.